ThrombUS+: Wearable for continuous monitoring, risk prediction and immediate alert for deep vein thrombosis at the point of care

Deep vein thrombosis (DVT) poses a significant health risk, with potentially life-threatening consequences when left undetected. ThrombUS+ is set to redefine DVT care with an ambitious mission to develop an innovative wearable diagnostic device for point-of-care, operator-free, continuous monitoring.

DVT involves the formation of blood clots in deep veins, primarily in the lower limbs, leading to blood flow obstruction. Shockingly, up to two-thirds of DVT cases exhibit no clinical symptoms, making early diagnosis challenging. ThrombUS+ steps in to bridge this gap, bringing together a diverse team of experts spanning industry, technology, regulation, social science, and clinical trials.

Our interdisciplinary approach centers around creating a novel wearable diagnostic device utilizing autonomous, AI-driven DVT detection. This groundbreaking device incorporates wearable ultrasound hardware, impedance plethysmography, and light reflection rheography for immediate clot detection. Activity and physiological measurements will continuously assess DVT risk, supporting prevention through serious gaming. An intelligent decision support unit will provide real-time monitoring and alerts, with extended reality guiding users for optimal device utilization.

ThrombUS+ is designed for postoperative patients, those undergoing lengthy surgical procedures, cancer patients, bedridden individuals at home or in care units, and women during pregnancy and postpartum.

ThrombUS+ will leverage big datasets collected through three large-scale clinical studies for AI training. Validation will be carried out in clinical settings through one early feasibility study and one multi-center clinical trial.